Lymphomas: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan-Kettering Cancer Center is constantly working to develop new and improved treatments for people with lymphoma who are not helped by standard treatments. This research is conducted through our clinical trials program.

Our physicians lead a large number of clinical trials that test new drugs and drug combinations, look for genetic factors that are linked to lymphoma, and explore other strategies for improving treatment for both Hodgkin and non-Hodgkin lymphoma. Our clinical trials are based on our growing understanding of how lymphoma is distinctive from other cancers. This research is increasingly “translational,” bringing discoveries made in the research lab directly to the patient.

This activity means that choosing Memorial Sloan-Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our clinical research team is highly experienced in selecting patients who are mostly likely to benefit from a particular investigational therapy and can guide you through the process of selecting the most appropriate clinical trial.

Our research efforts fall into the following general categories:

New chemotherapy approaches

Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.

Pathway-directed (biologic) therapies

Our investigators are testing drugs designed to interrupt or inhibit the molecular processes tumor cells require to grow and spread.

Immune strategies

Memorial Sloan-Kettering has an active immunotherapy program testing investigational drugs that encourage the body's immune system to identify and react against cancer cells.

Tumor-directed therapies (radiolabeled antibodies)

Memorial Sloan-Kettering researchers are investigating the effectiveness of antibodies — proteins that specifically target cancer cells and carry radioactive molecules. These drugs can potentially kill cancer cells with radiation while minimizing exposure to the rest of the body.

Here you can find a continually updated listing of Memorial Sloan-Kettering's current clinical trials for patients with lymphomas. To learn more about a study, choose from the list below.

Showing 23 trials
Titlesort icon Investigator
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and Stem Cell Transplantation in Patients with B-cell Non-Hodgkin's Lymphoma
[Protocol 06-150]
Castro-Malaspina, Hugo, MD
A Phase I Study of Brentuximab Plus Combination Chemotherapy as Initial Therapy for Systemic Anaplastic Large Cell Lymphoma
[Protocol 11-092]
Horwitz, Steven, MD
A Phase I Study of Oral LEE011 in Patients with Advanced Solid Tumors or Lymphomas
[Protocol 10-211]
Gerecitano, John, MD, PhD
A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
[Protocol 11-085]
Segal, Neil, MD, PhD
A Phase I Study of PU-H71 in Patients with Advanced Cancer
[Protocol 11-041]
Gerecitano, John, MD, PhD
A Phase I/II Study of Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL)
[Protocol 05-103]
Gerecitano, John, MD, PhD
A Phase I/II Study of Sequential Chemoradiation Followed by Autologous Stem Cell Transplant in Patients with Untreated Advanced Mantle Cell Lymphoma
[Protocol 11-095]
Zelenetz, Andrew, MD, PhD
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
[Protocol 11-013]
Noy, Ariela, MD
A Phase I/II Trial of Vorinostat in Combination with Cyclophosphamide, Etoposide, Prednisone, and Rituximab for Elderly Patients with Relapsed Diffuse Large B-Cell Lymphoma
[Protocol 08-045]
Straus, David, MD
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174]
Gerecitano, John, MD, PhD
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224]
Lamanna, Nicole, MD
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125]
Omuro, Antonio, MD
A Phase II Study of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim PET Imaging
[Protocol 10-153]
Straus, David, MD
A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Protocol 11-059]
Gerecitano, John, MD, PhD
A Phase III Study of SGN-35 versus Placebo in Patients at High Risk of Residual Hodgkin Lymphoma After Autologous Stem Cell Transplant
[Protocol 10-027]
Moskowitz, Craig, MD
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180]
Kissane, David, MD
Biaxin (Clarithromycin)-Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
[Protocol 07-038]
Portlock, Carol, MD
Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
[Protocol 11-050]
Hamlin, Paul, MD
PDX-017: A Phase III Study of Pralatrexate Versus Observation in Patients with Peripheral T-Cell Lymphoma Following Initial Chemotherapy
[Protocol 10-212]
Horwitz, Steven, MD
Phase I Study of Xenogeneic CD20 DNA Vaccination in Patients with B-cell Lymphoma
[Protocol 07-100]
Palomba, M. Lia, MD
Phase III Study of Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
[Protocol 11-079]
Matasar, Matthew, MD
Risk-Adapted Therapy for Patients With Untreated Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B-Cell Lymphoma
[Protocol 08-026]
Moskowitz, Craig, MD
Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
[Protocol 09-063]
Noy, Ariela, MD